Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Comparative Study Between Pericapsular Nerve Group Block (PENG) And Pericapsular Nerve Group (PENG) Block Combined With Lateral Femoral Cutaneous Nerve (LFCN) Block for Positioning Analgesia Prior to Spinal Anesthesia in Hip Fracture Patients

NCT07687290 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-06-18
Last updated
2026-07-09

Condition(s) studied

Hip Fracture Surgeries

Investigational drug(s) / intervention(s)

PENG BlockLCFN blockbupivacaine 0.25%. →Xylocaine 2 % →

PENG Block: Pericapsular Nerve Group Block

LCFN block: Lateral Femoral Cutaneous Nerve block

bupivacaine 0.25%.: 0.25% of Bupivacaine (Bupivacaine 0.5% is added to Lidocaine 2% in the same volume)

Xylocaine 2 %: local infilteration at the insertion site

Study summary

To evaluate and compare the effectiveness of the Pericapsular Nerve Group (PENG) block alone versus the PENG block combined with the Lateral Femoral Cutaneous Nerve (LFCN) block in providing adequate analgesia for patient positioning during spinal anesthesia in individuals undergoing surgery for hip fracture.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Age 18-70 years. * ASA I-II. * Confirmed primary unilateral hip fracture. * Scheduled for surgery under spinal anesthesia. * Patients able to provide informed consent. Exclusion Criteria: * Allergy to local anesthetics. * Coagulopathy or on anticoagulant therapy. * Infection at injection site. * Pre-existing neurological deficits in the lower limbs. * Multiple trauma or polytrauma (If other injuries might interfere with positioning or pain scoring). * Previous surgery on the ipsilateral hip affecting anatomy or nerve distribution.

Primary outcome measure(s)

  • To compare the time taken to achieve optimal positioning for spinal anesthesia in both groups — from initiation of patient positioning until optimal positioning is achieved during the spinal anesthesia procedure
    time taken in seconds for positioning for spinal anesthesia 15 minutes post- block

Trial sites (1)

FacilityCityRegionStatus
Ain Shams University Cairo Egypt Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07687290 on ClinicalTrials.gov ↗ ← All trials in Egypt